Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
November 06, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024...
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
November 01, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
October 28, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6,...
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
October 17, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and...
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
October 04, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at...
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024 07:46 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024 07:05 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
September 03, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
August 30, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti® + Opfolda® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024...